Artemether-Lumefantrine Supplier and Exporter to Tanzania

Malaria is endemic across much of mainland Tanzania and Zanzibar and remains a leading cause of illness, particularly among young children and pregnant women. Artemisinin-based combination therapies such as Artemether-Lumefantrine are the recommended first-line treatment for uncomplicated malaria in Tanzania, procured across the public health system, private pharmacies, and donor-supported programmes. Demand for quality-assured ACTs spans national procurement, importers, and the private market.

Pharmaceutical products imported into Tanzania require registration with the Tanzania Medicines and Medical Devices Authority (TMDA). We work with Tanzanian importer and distributor partners to register Artemether-Lumefantrine for the Tanzanian market, providing the CTD and ACTD dossiers the TMDA requires, with regulatory assistance through the process. If you are an established Tanzanian importer looking to add a WHO-GMP ACT to your portfolio, we would like to hear from you.

We manufacture Artemether-Lumefantrine in 20/120 mg, 40/240 mg, and 80/480 mg strengths, in both standard and dispersible tablets for paediatric dosing, important given the malaria burden among Tanzanian children. Packaging and labelling can be configured to the Tanzanian market.

Once registered, Artemether-Lumefantrine can be supplied for Tanzanian government malaria procurement (including through the Medical Stores Department), donor and NGO health programmes, and private-market distribution, with competitive volume pricing, flexible packaging, and private labelling.

MOQ and pricing depend on strength, formulation, packaging, and volume. We handle export logistics and documentation for shipments to Tanzania through the port of Dar es Salaam. Request a quote with your requirements for exact terms.